Angiogenesis in human cancer: Implications in cancer therapy

European Journal of Internal Medicine

Volumn 14, Issue 8, 2003, Pages 459-469

  Bamias, Aristotle ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Angiogenesis; Cancer therapy; VEGF

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; ANTITHROMBIN III; BETA INTERFERON; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 2; IRINOTECAN; LENALIDOMIDE; PLASMINOGEN ACTIVATOR INHIBITOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROLACTIN; PROTEIN P53; RECOMBINANT ALPHA INTERFERON; SCH 221153; SEMAXANIB; THALIDOMIDE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; ZINC;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; BLEEDING; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CARCINOMA; CELL HETEROGENEITY; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; ENDOMETRIUM; ENDOTHELIUM CELL; GIANT CELL TUMOR; GLIOMA; HEMANGIOMA; HUMAN; HYPERTENSION; KAPOSI SARCOMA; KIDNEY CARCINOMA; MELANOMA; METASTASIS; MULTIPLE MYELOMA; NONHUMAN; PATHOPHYSIOLOGY; PREGNANCY; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEINURIA; REGULATORY MECHANISM; REVIEW; SOLID TUMOR; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR TUMOR; WOUND HEALING;

EID: 1142273367     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2003.10.003     Document Type: Review

References (111)

1. Folkman J. Tumor angiogenesis. Mendelsohn J., Howley P.M., Israel M.A., Liotta L.A. The Molecular Basis of Cancer. 1995;206-232 Saunders, Philadelphia.
2. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist. 5:(Suppl. 1):2000;3-10.
3. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer. 2:2002;727-739.
4. Eleutherakis-Papaiakovou V., Karali M., Kokkonouzis I., Tiliakos I., Dimopoulos M.A. Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach. Leuk. Lymphoma. 44:(6):2003;937-948.
5. Sholley M.M., Ferguson G.P., Seibel H.R., Montour J.L., Wilson J.D. Mechanisms of neovasculaization. Lab. Invest. 51:(6):1984;624-634.
6. Brooks P.C., Montgomery A.M.P., Rosenfeld M., et al. Integrin avb3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164.
7. Bischoff J. Approaches to studying cell adhesion molecules in angiogenesis. Trends Cell Biol. 5:1995;69-73.
8. Stromblad S., Cheresh D.A. Cell adhesion and angiogenesis. Trends Cell Biol. 6:1996;462-467.
9. Gasparini G., Brooks P.C., Biganzoli E., et al. Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin. Cancer Res. 4:1998;2625-2634.
10. Pasqualini R., Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 380:1996;364-366.
11. Burrows F.J., Derbyshire E.J., Tazzari P.L., et al. Upregulation of endoglin vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin. Cancer Res. 1:1995;1623-1634.
12. Chang S.S., Reuter V.E., Heston W.D., Bander N.H., Grauer L.S., Gaudin P.B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59:1999;3192-3198.
13. Neri D., Carnemolla B., Nissim A., et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat. Biotechnol. 15:1997;1271-1275.
14. Hiraoka N., Allen E., Apel I.J., Gyetko M.R., Weiss S.J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell. 95:1998;365-377.
15. Levy A.P., Levy N.S., Wegner S., Goldberg M.A. Transcriptional regulation of the rat vascular endothelial growth factor by hypoxia. J. Biol. Chem. 270:1995;13333-13340.
16. 2 tension. Proc. Natl. Acad. Sci. USA. 92:1995;5510-5514.
17. Salceda S., Caro J. Hypoxia-inducible factor 1 (HIF-1) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272:1997;22642-22647.
18. Jewell U.R., Kvietikova I., Scheid A., et al. Induction of HIF-1 in response to hypoxia is instantaneous. FASEB J. 15:2001;1312-1314.
19. Carmeliet P., Dor Y., Herbert J.M., et al. Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:1998;485-490.
20. Akagi Y., Liu W., Zebrowski B., Xie K., Ellis L.M. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-growth factor-1. Cancer Res. 58:1998;4008-4014.
21. Pal S., Claffey K.P., Dvorak H.F., Mukhopadhayay D. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J. Biol. Chem. 272:1997;27509-27512.
22. Rohan R.M., Fernandez A., Udagawa T., et al. Genetic heterogeneity of angiogenesis in mice. FASEB J. 14:2000;871-876.
23. Folkman J. What is the role of thymidine phosphorylase in tumor angiogenesis? J. Natl. Cancer Inst. 88:(16):1996;1091-1092.
24. Gnarra J.R., Zhou S., Merrill M.J., et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. USA. 93:1996;10589-10594.
25. Iliopoulos O., Levy A.P., Jiang C., Kaelin W.G. Jr., Goldberg M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA. 93:1996;10595-10599.
26. Mukhopadhyay D., Knebelmann B., Cohen H.T., Ananth S., Sukhatme V.P. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol. 17:1997;5629-5639.
27. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275.
28. Ivan M., Haberberger T., Gervasi D.C., et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc. Natl. Acad. Sci. USA. 99:2002;13459-13464.
29. Ziegler B.L., Valtieri M., Porada G.A., et al. KDR receptor: a key marker defining haemopoietic stem cells. Science. 285:1999;1553-1558.
30. Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60:2000;203-212.
31. Blau H.M., Banfi A. The well-tempered vessel. Nat. Med. 7:2001;532-534.
32. Shweiki D., Itin A., Stoffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:1992;843-845.
33. Hartmann A., Kunz M., Kostlin S., et al. Hypoxia-induced upregulation of angiogenin in human malignant melanoma. Cancer Res. 59:1999;1978-1987.
34. Fujiwaki R., Kohji I., Kanasaki H., et al. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum. Pathol. 33:(2):2002;213-219.
35. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 77:1999;527-543.
36. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7:2001;987-989.
37. Miyazono K., Okabe T., Urabe A., et al. Purification and properties of an endothelial cell growth factor from human platelets. J. Biol. Chem. 262:1987;4098-4103.
38. Moghaddam A., Bicknell R. Expression of platelet-derived endothelial cell growth factor in Escherichia Coli and confirmation of its thymidine phosphorylase activity. Biochemistry. 31:1992;12141-12146.
39. Fox S.B., Westwood M., Moghaddam A., et al. The angiogenic platelet-derived endothelial cell growth factor/thymidine phosphorylase is upregulated in breast cancer epithelium and endothelium. Br. J. Cancer. 73:1996;275-280.
40. Takayashi Y., Bucana C.D., Liu W., et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J. Natl. Cancer Inst. 88:1996;1146-1151.
41. Takebayashi Y., Akiyama S., Akiba S., et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J. Natl. Cancer Inst. 88:1996;1110-1117.
42. Friesel R., Kamoriya A., Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J. Cell Biol. 104:1987;689.
43. Singh R.K., Gutman M., Bucana C.D., et al. Interferons alpha and beta downregulate the expression of basic fibroblast growth factor in human carcinoma. Proc. Natl. Acad. Sci. USA. 92:1995;4562.
44. I.J. Fidler, R.S. Kerbel, L.M. Ellis, Biology of cancer angiogenesis, in: DeVita, Hellman, Rosenberg (Eds.), Cancer Principles and Practice of Oncology, sixth ed., Lippincott-Raven, Philadelphia.
45. Weidner N., Sample J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast cancer. New Engl. J. Med. 324:1991;1.
46. Zhang L., Conejo-Garcia J.R., Katsaros D., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New Engl. J. Med. 348:2003;203-213.
47. Takayashi Y., Kitadai Y., Bucana C.D., et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 72:1995;319-324.
48. Or R., Feferman R., Shoshan S. Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polivinyl alcohol sponges in guinea pigs. Exp. Hematol. 26:1998;217-221.
49. Takayashi Y., Clearly K.R., Mai M., Kitadai Y., Bucana C.D., Ellis L.M. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin. Cancer Res. 2:1996;1679-1684.
50. Nebeh K., Moehler T., Kraemer A., et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res. 7:2001;2675-2681.
51. Corral L.G., Haslett P.A.J., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a. J. Immunol. 163:1999;380-386.
52. Kruse F.E., Joussen A.M., Muller G.W., Rohrschneider K., Becker M.D., Volcker H.E. Thalidomide inhibits corneal angiogenesis by vascular endothelial growth factor. Graefe's Arch. Clin. Exp. Opthalmol. 236:1998;461-466.
53. Kneller A., Raanani P., Hardan I., et al. Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. Br. J. Haematol. 108:2000;391-393.
54. Tosi P., Zamagni E., Cellini C. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Hematologica. 87:2002;408-414.
55. Barlogie B., Tricot G., Anaissie E. Thalidomide in the management of multiple myeloma. Semin. Oncol. 28:2001;577-582.
56. Dimopoulos M.A., Zervas K., Kouvatseas G., et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann. Oncol. 12:2001;991-995.
57. Sweeney C.J., Miller K.D., Sissons S.E., et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 61:2001;3369-3372.
58. Little R.F., Wyvill K.M., Pluda J.M., et al. Activity of thalidomide in AIDS-related Kaposi sarcoma. J. Clin. Oncol. 18:(13):2000;2593-2602.
59. Fine H.A., Wen P.-Y., Maher E.A., et al. Phase II trial of thalidomide and carmustine for patients with recurrent high grade gliomas. J. Clin. Oncol. 21:2003;2299-2304.
60. Figg W.D., Arlen P., Gulley J., et al. A randomized phase II trial of docetaxel (Taxotere) plus thalidomide in androgen-independent prostate cancer. Semin. Oncol. 28:(4 Suppl. 5):2001;62-66.
61. Danson S., Lorigan P., Arance A., et al. Randomized phase II study of temozolomide given every 8 h or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J. Clin. Oncol. 21:2003;2551-2557.
62. Gluzman-Poltorak Z., Cohen T., Herzog Y., et al. Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165. J. Biol. Chem. 275:2000;18040-18045.
63. Bachelder R.E., Crago A., Chung J., et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 61:2001;5736-5740.
64. Bagnard D., Vaillant C., Khuth S.T., et al. Semaphorin 3A-vascular endothelial growth factor-165 balance mediates migration and apoptosis of neural progenitor cells by the recruitment of shared receptor. J. Neurosci. 21:2001;3332-3341.
65. Miao H.Q., Lee P., Lin H., et al. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J. 14:2000;2532-2539.
66. B.J. Giantonio, D. Levy, P.J. O'Dwyer, et al., Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): results from the Eastern Cooperative Oncology Group (ECOG) Study E2200, Proceedings of 2003 ASCO Meeting, Abstract No. 1024.
67. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of Bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New Engl. J. Med. 349:2003;427-434.
68. Miller K., Sweeney C., Sledge G. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 19:2001;1195-1206.
69. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:2000;1878-1886.
70. Teicher B., Sotomayor E., Huang Z. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 52:1992;6702-6704.
71. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:2000;1878-1886.
72. Wild R., Ghosh K., Dings R., et al. Carboplatin differentially induces the VEGF stress response in endothelial cells: potentiation of anti-tumor effects by combination treatment with antibody to VEGF. Proc. Am. Assoc. Cancer Res. 41:2000;307.
73. Klement G., Baruchel S., Rak J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105:2000;R15-R24.
74. Riedel F., Gotte K., Bergler W., et al. Expression of basic fibroblast growth factor protein and its down-regulation by interferons in head and neck cancer. Head Neck. 22:2000;183-189.
75. Folkman J., Ingber D. Inhibition of angiogenesis. Semin. Cancer Biol. 3:1992;89-96.
76. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7:2001;987-989.
77. Petit A.M., Rak J., Hung M.C., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151:1997;1523-1530.
78. Yen L., You X.L., Al Moustafa A.E., et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene. 19:2000;3460-3469.
79. Maity A., Pore N., Lee J., et al. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res. 60:2000;5879-5886.
80. Clarke K., Smith K., Gullick W.J., et al. Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. Br. J. Cancer. 84:2001;1322-1329.
81. Ciardiello F., Caputo R., Bianco R., et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 7:2001;1459-1465.
82. Viloria-Petit A., Crombet T., Jothy S., et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 61:2001;5090-5101.
83. McDermott U., Longley D.B., Johnston P.G. Molecular and biochemical markers in colorectal cancer. Ann. Oncol. 10:2002;235-245.
84. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin. Cancer Res. 6:2000;2420-2430.
85. Mohhamed S.I., Benhett P.F., Craig B.A., et al. Effects of the cyclooxygenase inhibitor, Piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 62:2002;356-358.
86. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:2000;1306-1311.
87. Soriano A.F., Helfrich B., Chan D.C., et al. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 59:1999;6178-6184.
88. Kishi K., Petersen S., Petersen C., et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 60:2000;1326-1331.
89. Kawamori T., Rao C.V., Seibert K. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:1998;409-412.
90. Steinbach G., Lynch P.M., Philips R.K.S., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New Engl. J. Med. 342:2000;1946-1952.
91. Csiki I., Dang T., Gonzales A., et al. Cyclooxygenase-2 (COX-2) inhibition+docetaxel (Txt) in recurrent non-small cell lung cancer (NSCLC): preliminary results of a phase II trial (TH0-0054). Proc. Am. Soc. Clin. Oncol. 21:2002;297a. [Abstract 1187].
92. Altorki N.K., Keretsztes R.S., Port J.L., et al. Celecoxib (Celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;26a. [Abstract 101].
93. Wood J., Bonjean K., Ruetz S., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther. 302:2002;1055-1061.
94. Wood J., Schnell C., Green J.R. Zoledronic acid, a potent inhibitor of bone resorption, inhibits proliferation and induces apoptosis in human endothelial cells in vitro and is anti-angiogenic in a murine growth factor implant model. Proc. Am. Soc. Clin. Oncol. 19:2000;664. [Abstract 2620].
95. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62:2002;6538-6544.
96. Santini D., Vincenzi B., Avvisati G., et al. Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 8:2002;1080-1084.
97. Relf M., LeJeune S., Scott P.A., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor ß-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57:1997;963-969.
98. Kim E., Moore J., Huang J., et al. All angiogenesis is not the same: distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms' tumor. J. Pediatr. Surg. 36:2001;287-290.
99. Kerbel R.S. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J. Clin. Oncol. 19:(Suppl. 18):2001;45S-51.
100. Durand R.E., Raleigh J.A. Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res. 58:1998;3547-3550.
101. Durand R.E., Sham E. The lifetime of hypoxic human tumor cells. Int. J. Radiat. Oncol. Biol. Phys. 42:1998;711-715.
102. Miller K.D., Sweeney C.J., Sledge G.W. The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann. Oncol. 14:2003;20-28.
103. Eberhard A., Kahlert S., Goede V., et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 60:2000;1388-1393.
104. Low J.A., Johnson M.D., Bone E.A., et al. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin. Cancer Res. 2:1996;1207-1214.
105. Pluen A., Boucher Y., Ramanujan S., et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial versus subcutaneous tumors. Proc. Natl. Acad. Sci. USA. 98:2001;4628-4633.
106. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315-328.
107. O'Reilly M.S., Holmgren L., Chen C., et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2:1996;689-692.
108. Sood A.K., Seftor E.A., Fletcher M.S., et al. Molecular determinants of ovarian cancer plasticity. Am. J. Pathol. 158:2001;1279-1288.
109. Thomas J., Schiller J., Lee F., et al. A phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin. Proc. Am. Soc. Clin. Oncol. 20:2001;70a. [Abstract 274].
110. Miller K., Haney L., Pribluda V., et al. A phase I safety, pharmacokinetic and pharmacodynamic study of 2-methoxyestradiol in patients with refractory metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;43a. [Abstract 170].
111. Dancey J.E., Freidlin B. Targeting epidermal growth factor receptor-are we missing the mark? Lancet. 362:(9377):2003;62-64.